STAAR Surgical Company
NASDAQ Global MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- STAAR Surgical Company (NasdaqGS: STAA), founded in 1982 and headquartered in Lake Forest, California, designs, develops, manufactures and markets implantable lenses for the eye with companion delivery systems intended to provide visual freedom and lessen or eliminate reliance on glasses or contact lenses. The company's principal products include the EVO ICL family of phakic intraocular lenses (IOLs) made from proprietary Collamer material for correcting myopia, astigmatism, hyperopia and presbyopia; the Visian ICL family of phakic IOLs; and other refractive surgery solutions including cataract IOLs and related instruments, with over 3 million Collamer lenses sold worldwide to date. STAAR operates in the global ophthalmology industry across more than 75 countries through direct sales, subsidiaries and distributors, with facilities in the United States, Switzerland and other regions. In recent developments, STAAR amended its merger agreement with Alcon Inc. to include a 30-day go-shop period and adjourned the shareholder vote on Alcon's $1.5 billion acquisition offer, valued at $28 per share, to allow evaluation of alternatives amid opposition from investors including Broadwood Partners, which purchased over $41 million in shares in November 2025 and seeks to call a special meeting to remove three board directors. The company also reported preliminary third-quarter 2025 revenue of $94.7 million, a 6.9% year-over-year increase.
Staar Surgical Co (STAA) Shares Surge 3.4% -- What GF Score of 80 Tells Investors
STAAR Surgical Q2 Earnings Call Highlights
STAAR Surgical Company (STAA) Q2 2026 Earnings Call Transcript
Staar Surgical (STAA) Surpasses Q2 Earnings and Revenue Estimates
STAAR Surgical Reports Second Quarter 2026 Results
Staar Surgical (STAA) Upgraded to Strong Buy: What Does It Mean for the Stock?
STAAR Surgical Appoints Warren Foust as President and Chief Executive Officer
STAAR Surgical's Punishment For Opacity Is Just
Caution Lingers for STAAR Surgical Amid Middle East Geopolitical Tensions
STAAR Surgical Announces Preliminary Net Sales for Second Quarter 2026
Hedge Fund Broadwood Capital Added Over 1 Million Shares of STAAR Surgical to Its Position. Here's What That Means for Investors.
Staar Surgical Co (STAA) Stock Down 7.3% -- Now Undervalued? GF Score: 81/100
STAAR Surgical Company (STAA) Discusses Differentiation of EVO ICL Technology and Market Trends in Refractive Surgery Transcript
STAAR Surgical Announces Participation in Upcoming Investor Conferences
STAAR Surgical Q1 2026: Early Signs Of A Durable Turnaround
Why It's Time To Take Profits In This Top-Rated Medical Stock
STAAR Surgical Company (STAA) Q1 2026 Earnings Call Transcript
STAAR Surgical Q1 Earnings Call Highlights
Compared to Estimates, Staar Surgical (STAA) Q1 Earnings: A Look at Key Metrics
Staar Surgical (STAA) Tops Q1 Earnings and Revenue Estimates